The S&P/ASX 50 index is home to 50 of the largest listed companies on the Australian share market. This means the index is home to many of the highest quality and most well-known companies that the ANZ region has to offer.
Two ASX 50 shares to consider are below:
CSL Limited (ASX: CSL)
CSL is a biotechnology company that manufactures and develops a portfolio of leading therapies and vaccines. This includes flu vaccines, immunoglobulins, and countless other plasma-based products. It also operates one of the most wide-reaching plasma collection networks globally.
And while plasma collections have been difficult during the pandemic, one leading broker believes that the headwinds are easing. According to a recent note out of Citi, it believes that collection volumes will return to 2019 levels during the second half of 2021. This is thanks to the positive progress being made in the United States in respect to vaccine rollouts.
In light of this, Citi believes the recent weakness in the CSL share price has created a buying opportunity for investors. Its analysts have put a buy rating and $310.00 price target on its shares.
Lendlease Group (ASX: LLC)
Another ASX 50 share to look at is this global property and infrastructure company.
After a few years of struggles, Lendlease is now going through a major transformation. This has seen the company divest its engineering business and launch a new strategy which aims to shift its earnings mix and business model to be more like Goodman Group (ASX: GMG).
Goldman Sachs believes this strategy shift is a big positive and has put a buy rating and $16.54 price target on the company's shares.
Its analysts believe that Lendlease's shares are likely to re-rate to higher multiples once it starts to demonstrate that it is executing its new strategy successfully.
